T1 relaxation time analysis in predicting hepatic dysfunction and prognosis in patients with HCC undergoing...

To evaluate the value of T1 mapping in predicting hepatic dysfunction and prognosis in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).

100 consecutive patients with treatment-naive HCC treated with TACE were prospectively analyzed. Clinical, laboratory, and MRI parameters (liver and tumor T1 relaxation times (T1_L, T1_T)) before and/or following TACE were measured and calculated. Clinical parameters included the Child-Turcotte-Pugh (CTP) classification, Barcelona Clinic Liver Cancer Classification (BCLC) criteria, and albumin-bilirubin (ALBI) score. Laboratory parameters were the gold standard for hepatic dysfunction. T1_L and T1_T were combined by stepwise multivariate logistic regression to yield a T1-related probability index (T1_com) for further analysis. Study endpoints included hepatic dysfunction and progression-free survival (PFS) rate.

38 patients (38%) were diagnosed with hepatic dysfunction following TACE. There was no significant difference in clinical parameters between the groups with and without hepatic dysfunction. Logistic regression analysis showed that T1_L and T1_T were independent risk factors for assessing hepatic dysfunction. T1_com showed a better AUC than T1_L and T1_T (0.81 vs. 0.76 and 0.69, P = 0.007 and 0.006). Patients with low T1_com (≤0.42) showed a better median PFS than patients with high T1_com (>0.42) (167.0 vs. 215.9 days, P = 0.010). In comparison, CTP, BCLC, and ALBI scores were not statistically significant in predicting PFS in HCC patients treated with TACE (P > 0.05).

Compared with widely used clinical parameters, T1 was more capable of predicting hepatic dysfunction after TACE. Stratification of patients with HCC undergoing TACE according to T1 may help clinicians to develop treatment strategies in preventing the occurrence of hepatic dysfunction and improving individual prognoses.